High-dose trivalent influenza vaccine: safety and immunogenicity

Citations Over Time

Abstract

Adults aged 65 years or older suffer the most severe health effects of seasonal flu. Although the influenza vaccine is effective in preventing influenza virus infection and its complications, it is not as effective in the elderly due to age-associated immunosenescence phenomenon. Since 2009, a high-dose trivalent influenza vaccine has been approved in the United States for the immunization of people ≥ 65 years with an antigen concentration four times higher than the standard vaccine. Multiple clinical trials carried out over different seasons, and using different methodologies, have shown that the high-dose trivalent influenza vaccine is not only more effective, but it also has a similar safety profile and is more immunogenic than the standard dose vaccine in the prevention of flu and its complications in the elderly. This document reviews the current scientific evidence on the safety and immunogenicity of high-dose influenza vaccine in people aged 65 years and over, and includes information from randomized clinical trials, observational studies with data from real clinical practice, and systematic reviews, and meta-analysis.

Related Papers

• → Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: Do children of all ages respond equally?(2010)32 cited
• → A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population(2009)26 cited
• → Summary of the NACI Statement on Seasonal Influenza Vaccine for 2017–2018(2017)15 cited
• → Summary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2016–2017(2016)7 cited
• → A New Mammalian Cell Culture-Derived Influenza Vaccine is as Safe as, and Immunogenically Non-Inferior to, an Egg-Based Influenza Vaccine(2008)